

## Idogen Q4 2022 - The future is contingent on funding

Redeye leaves its comments on Idogen following its Q4 report. The company has paused its ongoing phase I/IIa-trial and the financial position is stressed. We lower our fair value range accordingly.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Idogen Q4 2022 - The future is contingent on funding](#)